[68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time?
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
- -
- focal/diffuse (when the pattern changed/alternated from diffuse to focal);
- -
- focal/absent (when the pattern changed/alternated from focal to absent);
- -
- diffuse/absent (when the pattern changed/alternated from diffuse to absent);
- -
- absent/focal/diffuse (when all the described patterns were observed in the same pt at different time-points).
3. Results
4. Discussion
5. Conclusions
6. Pertinent Findings
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kwekkeboom, D.J.; Kam, B.L.; Van Essen, M.; Teunissen, J.J.M.; Van Eijck, C.H.J.; Valkema, R.; De Jong, M.; De Herder, W.W.; Krenning, E.P. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer 2010, 17, R53–R73. [Google Scholar] [CrossRef] [Green Version]
- Cascini, G.L.; Cuccurullo, V.; Tamburrini, O.; Rotondo, A.; Mansi, L. Peptide imaging with somatostatin analogues: More than cancer probes. Curr. Radiopharm. 2013, 6, 36–40. [Google Scholar] [CrossRef]
- Antunes, P.; Ginj, M.; Zhang, H.; Waser, B.; Baum, R.P.; Reubi, J.C.; Maecke, H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur. J. Nucl. Med. 2007, 34, 982–993. [Google Scholar] [CrossRef] [Green Version]
- Reubi, J.C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur. J. Pediatr. 2003, 30, 781–793. [Google Scholar] [CrossRef]
- Bozkurt, M.F.; Virgolini, I.; Balogova, S.; Beheshti, M.; Rubello, D.; Decristoforo, C.; Ambrosini, V.; Kjaer, A.; Delgado-Bolton, R.; Kunikowska, J.; et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 1588–1601. [Google Scholar] [CrossRef]
- Reubi, J.C.; Maurer, R.; Von Werder, K.; Torhorst, J.; Klijn, J.G.; Lamberts, S.W. Somatostatin receptors in human endocrine tumors. Cancer Res. 1987, 47, 551–558. [Google Scholar]
- Reubi, J.; Kvols, L.; Krenning, E.; Lamberts, S. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990, 39, 78–81. [Google Scholar] [CrossRef]
- Marko, J.; Lamba, R.; Miller, F.; Buchman, A.; Spies, S.; Nikolaidis, P. OctreoScan Positive Crohn’s Disease Mimicking an Ileal Carcinoid Tumor. J. Clin. Gastroenterol. 2008, 42, 66–68. [Google Scholar] [CrossRef]
- Lebtahi, R.; Cadiot, G.; Marmuse, J.P.; Vissuzaine, C.; Petegnief, Y.; Courillon-Mallet, A.; Cattan, D.; Mignon, M.; Le Guludec, D. False-positive somatostatin receptor scintigraphy due to an accessory spleen. J. Nucl. Med. 1997, 38, 1979–1981. [Google Scholar]
- Al-Ibraheem, A.; Bundschuh, R.A.; Notni, J.; Buck, A.; Winter, A.; Wester, H.-J.; Schwaiger, M.; Scheidhauer, K. Focal uptake of 68Ga-DOTATOC in the pancreas: Pathological or physiological correlate in patients with neuroendocrine tumours? Eur. J. Pediatr. 2011, 38, 2005–2013. [Google Scholar] [CrossRef]
- Brabander, T.; Teunissen, J.; Kwekkeboom, D. Physiological Uptake in the Pancreatic Head on Somatostatin Receptor Scintigraphy Using [111In-DTPA]Octreotide. Clin. Nucl. Med. 2017, 42, 15–19. [Google Scholar] [CrossRef]
- Zhernosekov, K.P.; Filosofov, D.V.; Baum, R.P.; Aschoff, P.; Bihl, H.; Razbash, A.A.; Jahn, M.; Jennewein, M.; Rösch, F. Processing of Generator-Produced 68Ga for Medical Application. J. Nucl. Med. 2007, 48, 1741–1748. [Google Scholar] [CrossRef]
- Elsinga, P.; The Radiopharmacy Committee of the EANM; Todde, S.; Penuelas, I.; Meyer, G.; Farstad, B.; Faivre-Chauvet, A.; Mikolajczak, R.; Westera, G.; Gmeiner-Stopar, T.; et al. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur. J. Pediatr. 2010, 37, 1049–1062. [Google Scholar] [CrossRef] [Green Version]
- Kumar, U.; Sasi, R.; Suresh, S.; Patel, A.; Thangaraju, M.; Metrakos, P.; Patel, S.C.; Patel, Y.C. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: A quantitative double-label immunohistochemical analysis. Diabetes 1999, 48, 77–85. [Google Scholar] [CrossRef]
- Gabriel, M.; Decristoforo, C.; Kendler, D.; Dobrozemsky, G.; Heute, D.; Uprimny, C.; Kovacs, P.; von Guggenberg, E.; Bale, R.; Virgolini, I.J. 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT. J. Nucl. Med. 2007, 48, 508–518. [Google Scholar] [CrossRef]
- Prasad, V.; Baum, R.P. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: Characterization of uptake in normal organs and tumor lesions. Q. J. Nucl. Med. Mol. Imaging 2010, 54, 61–67. [Google Scholar]
- Castellucci, P.; Ucha, J.P.; Fuccio, C.; Rubello, D.; Ambrosini, V.; Montini, G.C.; Pettinato, V.; Malizia, C.; Lodi, F.; Fanti, S. Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT. J. Nucl. Med. 2011, 52, 886–890. [Google Scholar] [CrossRef] [Green Version]
- Krausz, Y.; Rubinstein, R.; Appelbaum, L.; Mishani, E.; Orevi, M.; Fraenkel, M.; Tshori, S.; Glaser, B.; Bocher, M.; Salmon, A.; et al. Ga-68 DOTA-NOC Uptake in the Pancreas: Pathological and Physiological Patterns. Clin. Nucl. Med. 2012, 37, 57–62. [Google Scholar] [CrossRef]
- Lakhotia, R.; Jhawar, S.; Malayeri, A.A.; Millo, C.; Del Rivero, J.; Ahlman, M.A. Incidental 68Ga-DOTATATE uptake in the pancreatic head: A Case Report and a Unique Opportunity to Improve Clinical Care. Medicine 2020, 99, e20197. [Google Scholar] [CrossRef]
- Kunikowska, J.; Krolicki, L.; Pawlak, D.; Zerizer, I.; Mikołajczak, R. Semiquantitative Analysis and Characterization of Physiological Biodistribution of 68Ga-DOTA-TATE PET/CT. Clin. Nucl. Med. 2012, 37, 1052–1057. [Google Scholar] [CrossRef]
- Jacobsson, H.; Larsson, P.; Jonsson, C.; Jussing, E.; Grybäck, P. Normal Uptake of 68Ga-DOTA-TOC by the Pancreas Uncinate Process Mimicking Malignancy at Somatostatin Receptor PET. Clin. Nucl. Med. 2012, 37, 362–365. [Google Scholar] [CrossRef]
- Mapelli, P.; Tam, H.H.; Sharma, R.; Aboagye, E.O.; Al-Nahhas, A. Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas: Validation with Morphological Imaging. Nucl. Med. Commun. 2014, 35, 613–619. [Google Scholar] [CrossRef] [PubMed]
- Gelsomino, F.; Ambrosini, V.; Melotti, B.; Sperandi, F.; Ardizzoni, A. Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK -Rearranged NSCLC. J. Thorac. Oncol. 2016, 11, e99–e101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, X.; Zielinski, M.C.; Misawa, R.; Wen, P.; Wang, T.-Y.; Wang, C.-Z.; Witkowski, P.; Hara, M. Quantitative Analysis of Pancreatic Polypeptide Cell Distribution in the Human Pancreas. PLoS ONE 2013, 8, e55501. [Google Scholar] [CrossRef] [Green Version]
- Bunning, J.; Merchant, S.H.; Crooks, L.A.; Hartshorne, M.F. Indium-111 Pentetreotide Uptake by Pancreatic Polypeptide Cell Hyperplasia: Potential Pitfall in Somatostatin Receptor Scintigraphy. Pancreas 2007, 35, 372–375. [Google Scholar] [CrossRef] [PubMed]
- Albers, M.B.; Maurer, E.; Klöppel, G.; Bartsch, D.K. Pancreatic Polypeptide-Rich Islets in the Posterior Portion of the Pancreatic Head—A Tumor Mimic in Somatostatin Receptor Scintigraphy. Pancreas 2014, 43, 648–650. [Google Scholar] [CrossRef] [PubMed]
- De La Cueva, L.; Lloro, P.; Sangrós, M.J.; Vélez, L.L.; Navarro, P.; Sarria, L.; Álvarez, S.; Abós, D. Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy. Clin. Transl. Oncol. 2017, 19, 915–920. [Google Scholar] [CrossRef]
- Oh, D.; Choi, H.; Paeng, J.C.; Kang, K.W.; Cheon, G.J. A Negative Correlation Between Blood Glucose Level and 68 Ga-DOTA-TOC Uptake in the Pancreas Uncinate Process. Nucl. Med. Mol. Imaging 2022, 56, 52–58. [Google Scholar] [CrossRef]
- Watanabe, M.; Nakamoto, Y.; Koyasu, S.; Ishimori, T.; Yasoda, A.; Togashi, K. The influence of elevated hormone levels on physiologic accumulation of 68Ga-DOTATOC. Ann. Nucl. Med. 2018, 32, 191–196. [Google Scholar] [CrossRef]
Indication | Number of pts | % |
---|---|---|
Staging | 13 | 7.6 |
Restaging after surgery | 21 | 12.2 |
Before PRRT | 1 | 0.6 |
Suspected relapse | 8 | 4.7 |
Restaging after therapy | 5 | 2.9 |
Interim PET/CT | 45 | 26.2 |
Unknown primary tumor | 13 | 7.6 |
Suspicion of NEN | 46 | 26.7 |
Follow-up | 20 | 11.6 |
Total | 172 | 100 |
Primary Tumor Site | Number of pts | % | |
---|---|---|---|
GEP | |||
Pancreas | 33 | 19.2 | |
Ileum | 48 | 27.9 | |
Ileum + duodenum | 1 | 0.6 | |
Duodenum | 1 | 0.6 | |
Jejunum | 3 | 1.7 | |
Appendix | 4 | 2.3 | |
Colo/rectal | 3 | 1.7 | |
Gastric | 7 | 4.1 | |
Lung | 15 | 8.7 | |
CUP | 18 | 10.5 | |
MEN | 3 | 1.7 | |
Other | Middle ear | 2 | 1.2 |
Kidney | 1 | 0.6 | |
Skin (merckel cells carcinoma) | 1 | 0.6 | |
Submandibular gland | 1 | 0.6 | |
Breast | 1 | 0.6 | |
Mediastinum | 4 | 2.3 | |
Paraganglioma | 2 | 1.2 | |
Adrenals | 5 | 2.9 | |
Adrenal + lung | 1 | 0.6 | |
Thyroid | 2 | 1.2 | |
Suspected NEN not confirmed at biopsy/FU * | 16 | 9.3 | |
Total | 172 | 100 |
Previous Scans Number | Number of pts |
---|---|
1 | 27 |
2 | 13 |
3 | 7 |
4 | 7 |
5 | 7 |
6 | 3 |
7 | 2 |
8 | 1 |
9 | 1 |
10 | 2 |
11 | 3 |
14 | 1 |
20 | 1 |
100 | 75 |
Pattern | Number of pts% | ||
---|---|---|---|
Stable | |||
Absent | 43 | 57.3 | |
Focal | 2 | 2.7 | |
Diffuse | 9 | 12.0 | |
Variable | |||
focal/diffuse | 5 | 6.7 | |
focal/absent | 4 | 5.3 | |
diffuse/absent | 11 | 14.7 | |
absent/focal/diffuse | 1 | 1.3 | |
Total | 75 | 100 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tabacchi, E.; Fortunati, E.; Argalia, G.; Zanoni, L.; Calabrò, D.; Telo, S.; Campana, D.; Lamberti, G.; Ricci, C.; Casadei, R.; et al. [68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time? Cancers 2022, 14, 3541. https://doi.org/10.3390/cancers14143541
Tabacchi E, Fortunati E, Argalia G, Zanoni L, Calabrò D, Telo S, Campana D, Lamberti G, Ricci C, Casadei R, et al. [68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time? Cancers. 2022; 14(14):3541. https://doi.org/10.3390/cancers14143541
Chicago/Turabian StyleTabacchi, Elena, Emilia Fortunati, Giulia Argalia, Lucia Zanoni, Diletta Calabrò, Silvi Telo, Davide Campana, Giuseppe Lamberti, Claudio Ricci, Riccardo Casadei, and et al. 2022. "[68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time?" Cancers 14, no. 14: 3541. https://doi.org/10.3390/cancers14143541